Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus gemcitabine/cisplatin versus gemcitabine/cisplatin in first-line wild-type HRAS advanced urothelial carcinoma
2009-015119-42Phase 2Completed
- Sponsor
- GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH
- Start
- Feb 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of panitumumab, gemcitabine and cisplatin in transitional cell carcinoma (TCC) and transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH. Primary endpoint: Progression-free survival rate at 12 months. Started Feb 2010; status: completed.
02
Drugs
panitumumabgemcitabinecisplatin
03
Conditions
transitional cell carcinoma (TCC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2009-015119-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015119-42.